KLK4 and COVID-19: It was hypothesized that blocking the B2R and inhibiting plasma kallikrein activity might have an ameliorating effect on early disorders caused by COVID-19 and might prevent acute respiratory distress syndrome [99,100], besides being able to collaborate with indirectly response to anti-inflammatory agents.